The Categorisation Commission for Medicinal Products at the Ministry of Health approved the inclusion of other innovative medicinal products in the list of categorised medicinal products at the May meeting. Health insurance companies will thus treat patients with severe haemophilia, melanoma, breast cancer, but also migraines or other diseases.
Minister of Health of the Slovak Republic Zuzana Dolinková recalled that the faster entry of innovative medicines is in line with the government programme statement. The aim is to get medicines to patients in the standard way, i.e. after the categorization process, where their cost-effectiveness is proven and they become available to all patients who need them,' said the Minister for Health. As she added, after each meeting of the CEC, other and other modern medicines are included, which will significantly help in the treatment of often very serious diseases.
Since January 2024, more than 180 medicinal products have been included in the list of categorised medicinal products. It includes generic/biosimilar medicines, innovative medicines and medicines with the status of -orphan drugs, which are intended for rare diseases. The list of categorised medicines is updated monthly.
Medicinal products approved at the May meeting of the Categorisation Committee for Medicinal Products will be included in the categorisation list, i.e. covered by health insurance, from 1 August 2024.
Innovative medicinal products included in the categorisation list from August 2024:
- Hemlibra – contains the active substance emicizumab. For Hemlibra another indication was approved - treatment of severe haemophilia A (congenital factor VIII deficiency) without a factor VIII inhibitor. This is a solution for injection.
- Kimmtrak is a medicine that contains the active substance taintafusp. For Kimmtrak, an indication for the treatment of uveal melanoma has been approved. This is a solution for infusion.
- Trodelvy – contains the active substance sacituzumab govitecan. The indication for treatment of breast cancer has been approved for Trodelvy. This is a solution for infusion.
- Vyvgart Þ medicine contains the active substance efgartigimod alfa. For Vyvgart, an indication for the treatment of adult patients with generalised myasthenia gravis has been approved. It is a solution for infusion.
- Vyepti – contains the active substance eptinezumab. For Vyepti, an indication of the treatment of migraine in adult patients has been approved. This is a solution for infusion.
For more details on the medicines, see:https://www.sukl.sk/